Johnson & Johnson buy stratec
Summary
This prediction ended on 05.11.21 with a price of €142.02. The prediction had a final performance of 22.39%. Dividends of €8.52 are taken into consideration when calculating the performance. stratec has 50% into this predictionJohnson Johnson is a multinational company that focuses on the development, manufacturing, and marketing of a wide range of consumer health products, medical devices, and pharmaceuticals. The company was founded in 1886 and is headquartered in New Jersey, USA. It operates in more than 60 countries and has a diverse portfolio of popular brands including Band-Aid, Tylenol, and Neutrogena. As of 2021, Johnson Johnson has a market capitalization of over $435 billion and is listed on the New York Stock Exchange under the symbol JNJ.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Johnson & Johnson | 0.956% | 0.956% | -1.421% | 5.442% |
iShares Core DAX® | -1.471% | 1.895% | 25.178% | 22.236% |
iShares Nasdaq 100 | -0.486% | 4.395% | 29.415% | 42.175% |
iShares Nikkei 225® | -2.115% | 2.450% | 20.561% | 6.454% |
iShares S&P 500 | 0.394% | 3.118% | 29.456% | 42.672% |
Comments by stratec for this prediction
In the thread Johnson & Johnson diskutieren
stratec stimmt der Outperform-Einschätzung der institutionellen Analysten zu
stratec stimmt am 11.01.2019 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 146.32$ zu.
In the thread Trading Johnson & Johnson